Nominate your peers and colleagues for HFSA Awards through February 27!
2023 | HFSA

New Episode of the Heart Failure Beat Discusses the Top Takeways from 2022 Part II

HFSA News Podcasts

Tune into this episode of HF Beat to hear co-hosts, Michael Beasley, MD and Priya Umapathi, MD, interview the current and immediate-past presidents of the HFSA, Drs. John Teerlink and Mark Drazner, discussing the most significant developments in heart failure cardiology during 2022.

Priya also introduces her new episode segment "From Failure to Function," which summarizes the latest heart failure research presented at meetings around the world.

Guest: 

  • John Teerlink, MD, FHFSA, HFSA President and Director of Heart Failure and Echocardiography Laboratory at San Francisco Veterans Affairs Medical Center, San Francisco, CA @johnteerlinkmd


 


References / Notes 
Important Note: At the time of this recording, the the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) vote on omecamtiv mecarbil had not occurred. As of December 13, 2022, the committee “voted 8 to 3 that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF).” Read the full press release.